Pharma Rev:鱼类多肽或可有效治疗心血管疾病

2015-01-15 佚名 生物谷

近日,发表在国际杂志Pharmacological Reviews上的一篇综述文章中,来自莱斯特大学的研究人员表示,来源于鱼类机体中的多肽或可用于有效治疗心血管疾病。 文章中,研究者David Lambert表示,我们首次从硬骨鱼中分离出了一种名为硬骨鱼紧张肽II(UII),其可以激活一种名为UT的G蛋白偶联受体,从而调节包括细胞内钙质在内的一系列信号路径的激活;更有意思的是这种多肽可以收缩血管

近日,发表在国际杂志Pharmacological Reviews上的一篇综述文章中,来自莱斯特大学的研究人员表示,来源于鱼类机体中的多肽或可用于有效治疗心血管疾病。

文章中,研究者David Lambert表示,我们首次从硬骨鱼中分离出了一种名为硬骨鱼紧张肽II(UII),其可以激活一种名为UT的G蛋白偶联受体,从而调节包括细胞内钙质在内的一系列信号路径的激活;更有意思的是这种多肽可以收缩血管。

研究者发现,UII可以调节包括心血管系统、肾脏及中枢神经系统在内的一系列系统的生物学活性。

Lambert教授表示,我们已经对这种名为UII的多肽进行了很多年的研究了,其可以表现出一种非常有意思及其潜在的药理学特性,后期我们将以此为基础涉及新型的小分子药物,并对其进行评估,以期待其早日用于治疗一系列心血管疾病中去。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787160, encodeId=7c8e1e8716078, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Feb 05 10:29:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908179, encodeId=26c419081e954, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Oct 13 12:29:00 CST 2015, time=2015-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497862, encodeId=6c79149e8625d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530031, encodeId=d99e1530031d4, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619406, encodeId=a77c1619406e6, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14388, encodeId=6e4814388e2, content=老东东了,十年前国内就有研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.98.**, createdTime=Thu Jan 15 19:21:00 CST 2015, time=2015-01-15, status=1, ipAttribution=)]
    2015-02-05 jj000001
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787160, encodeId=7c8e1e8716078, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Feb 05 10:29:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908179, encodeId=26c419081e954, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Oct 13 12:29:00 CST 2015, time=2015-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497862, encodeId=6c79149e8625d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530031, encodeId=d99e1530031d4, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619406, encodeId=a77c1619406e6, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14388, encodeId=6e4814388e2, content=老东东了,十年前国内就有研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.98.**, createdTime=Thu Jan 15 19:21:00 CST 2015, time=2015-01-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787160, encodeId=7c8e1e8716078, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Feb 05 10:29:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908179, encodeId=26c419081e954, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Oct 13 12:29:00 CST 2015, time=2015-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497862, encodeId=6c79149e8625d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530031, encodeId=d99e1530031d4, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619406, encodeId=a77c1619406e6, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14388, encodeId=6e4814388e2, content=老东东了,十年前国内就有研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.98.**, createdTime=Thu Jan 15 19:21:00 CST 2015, time=2015-01-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787160, encodeId=7c8e1e8716078, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Feb 05 10:29:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908179, encodeId=26c419081e954, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Oct 13 12:29:00 CST 2015, time=2015-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497862, encodeId=6c79149e8625d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530031, encodeId=d99e1530031d4, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619406, encodeId=a77c1619406e6, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14388, encodeId=6e4814388e2, content=老东东了,十年前国内就有研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.98.**, createdTime=Thu Jan 15 19:21:00 CST 2015, time=2015-01-15, status=1, ipAttribution=)]
    2015-01-17 fusion
  5. [GetPortalCommentsPageByObjectIdResponse(id=1787160, encodeId=7c8e1e8716078, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Feb 05 10:29:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908179, encodeId=26c419081e954, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Oct 13 12:29:00 CST 2015, time=2015-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497862, encodeId=6c79149e8625d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530031, encodeId=d99e1530031d4, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619406, encodeId=a77c1619406e6, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14388, encodeId=6e4814388e2, content=老东东了,十年前国内就有研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.98.**, createdTime=Thu Jan 15 19:21:00 CST 2015, time=2015-01-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1787160, encodeId=7c8e1e8716078, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Feb 05 10:29:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908179, encodeId=26c419081e954, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Oct 13 12:29:00 CST 2015, time=2015-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497862, encodeId=6c79149e8625d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530031, encodeId=d99e1530031d4, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619406, encodeId=a77c1619406e6, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jan 17 00:29:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14388, encodeId=6e4814388e2, content=老东东了,十年前国内就有研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.98.**, createdTime=Thu Jan 15 19:21:00 CST 2015, time=2015-01-15, status=1, ipAttribution=)]
    2015-01-15 175.9.98.**

    老东东了,十年前国内就有研究

    0

相关资讯

Lancet Diab & Endo:肥胖可导致糖尿病和心血管疾病提早数十年,甚至短寿

研究背景: 尽管普遍认为体重过重会增加心血管疾病和2型糖尿病的风险,但医务工作者仍然缺乏一个有意义的临床度量标准。我们预计体重的增加将导致糖尿病和心血管疾病相关的质量调整寿命年的减少和寿命损失年的增加。 研究方法: 我们开发了一种疾病刺激模型来评估糖尿病和心血管疾病的年风险情况,并且将BMI处在25-25-<30 kg/m2 (超重), 30-<35 kg/m2 (

AHA 2014:郭艺芳:无心脑血管病患者需用阿司匹林吗?

血栓栓塞事件是心血管疾病致死致残的主要机制之一。长期以来,阿司匹林在心血管疾病防治中一直发挥着重要作用。确凿证据表明,对于已经发生心血管疾病的患者,长期应用小剂量阿司匹林进行二级预防可以显著降低心肌梗死、卒中以及心脏性死亡与全因死亡率。因而,阿司匹林被视为心血管疾病二级预防的基石。然而近年来,关于小量阿司匹林在心血管疾病一级预防中作用一直存在争议。 2012年欧洲心血管疾病预防临床实践指

金元哲&韩硕:心血管疾病与性活动:新进展和指南解读

性活动是心血管疾病(CVD)患者及其伴侣生活质量的重要组成部分。性活动的减少和性功能的下降在CVD患者中常见,因此患者需要医生提供专业的建议及帮助。医生也同样面临性医学发展所带来的新的机遇与挑战,其中CVD患者性活动的安全性等相关问题受到更多的关注。 自1999年普林斯顿会议首次制定性活动与CVD风险的指南,第36届塞斯达会议,欧洲心脏病学会(ESC)对于CVD患者体力活动和体育运动

乔岩:红酒——法国人的美丽谎言?

法国人喜欢喝红酒,法国人心血管病发病率比其他欧美国家低,这是喝红酒的好处吗?医学证据表明,适量饮酒会升高具有心脏保护作用的好胆固醇,减轻胰岛素抵抗,降低糖尿病和心血管疾病风险,具有一定心脏保护作用。而红葡萄酒除了可以升高好胆固醇,还含有多酚和白藜芦醇等抗氧化剂,改善血管内皮功能,减轻炎症反应,可能有益心脏健康,也会降低肥胖和糖尿病风险。这也是把法国人心血管病死亡率低归结于红酒的主要原因,成为小

Medscape:肥胖会减寿8年

研究者预计,非常胖的人比体重正常者患糖尿病和心血管疾病的时间早了20年,并且比正常人少活8年。研究作者Steven A Grover医生说:“我们的这项发现是由临床意义的,在医生与患者谈论健康的生活方式有何益处时,可以引用此数据。也就是说,体重越重、年纪越轻的人,超重对健康的影响就越大。”该研究发表于近日的Lancet Diabetes & Endocrinology上。研究者评估了20-

睾酮疗法不会增加心血管疾病风险

近日,来自美国Intermountain医学中心心脏研究所的研究人员对进行睾酮补充疗法的男性进行研究发现,睾酮的补充并不会增加男性主要不良心脏事件,比如心脏病发作或中风的风险。 文章中,研究人员对5695名年龄在53岁至71岁间的男性进行研究,结果显示,相比持续性睾酮水平较低的个体来讲,接受睾酮补充达到正常水平或较高睾酮水平的男性个体患主要不良心脏事件的风险较低;较低的比率的心脏危险事件包括